Premium
TREATMENT OF MALIGNANCY‐ASSOCIATED HYPERCALCEMIA WITH NORETHISTERONE: A CASE REPORT
Author(s) -
ANDERSON CRAIG S.,
OLWENY CHARLES L. M.,
NEED ALLAN G.
Publication year - 1989
Publication title -
australian and new zealand journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 0004-8291
DOI - 10.1111/j.1445-5994.1989.tb01675.x
Subject(s) - medicine , malignancy , norethisterone , bone resorption , primary hyperparathyroidism , hyperparathyroidism , cancer , resorption , gastroenterology , endocrinology , population , health services , environmental health
Hypercalcemia is a common cause of morbidity in cancer patients. The mechanism of malignancy‐associated hypercalcemia includes increased bone resorption and decreased renal calcium clearance which also occur in primary hyperparathyroidism. Norethisterone can inhibit bone resorption and has recently been shown to be effective treatment for mild hyperparathyroidism in post menopausal women. We report the successful use for the first time of norethisterone (5 mg daily) in a case of malignancy‐associated hypercalcemia after other standard agents failed. (Aust NZ J Med 1989; 19: 51–54.)